Under the agreement, Delrus will distribute MagForce’s NanoTherm therapy in Russian Federation and Kazakhstan.

The LOI also includes Delrus’ financial and professional support for the regulatory approval of NanoTherm therapy in brain tumors and other indications in Russia, including pancreatic and prostate cancer.

Delrus president July Magadeev said they look forward to the opportunity to bring nanomedicine in oncology to the medical market in Russia and Kazakhstan and professionally support its usage among oncology specialists and in hospitals.